A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1
Information source: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Amphetamine-Related Disorders
Intervention: Reserpine (Drug)
Phase: Phase 1
Status: Active, not recruiting
Sponsored by: National Institute on Drug Abuse (NIDA) Official(s) and/or principal investigator(s):
Reese Jones, M.D., Principal Investigator, Affiliation: Langley Porter Psychiatric Institute
Summary
In this parallel group clinical pharmacology laboratory experiment, we will assess
pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous
methamphetamine dose and single oral doses of reserpine (0. 5 and 1. 0 mg) or placebo.
Clinical Details
Official title: Assessment of Interactions Between IV Methamphetamine and Reserpine
Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Primary outcome: CravingCardiovascular Subjective symptoms/Mood Effects CNS norepinephrine turnover
Detailed description:
In this parallel group clinical pharmacology laboratory experiment, we will assess
pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous
methamphetamine dose and single oral doses of reserpine (0. 5 and 1. 0 mg) or placebo.
Eligibility
Minimum age: 21 Years.
Maximum age: 45 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Please contact site for more details
Exclusion Criteria:
- Please contact site for more details
Locations and Contacts
U of CA, San Francisco, San Francisco, California 94143, United States
Additional Information
Starting date: January 2004
Last updated: October 25, 2007
|
